A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.

开始日期2023-10-10

申办/合作机构

Affimed GmbH

[+1]

NCT04074746

/ Active, not recruiting临床1/2期IIT

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer [NK] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as AFM13, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer growth in patients with CD30 positive AFM13-NK Hodgkin and Non-Hodgkin lymphomas.

开始日期2020-07-18

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT04101331

/ Completed临床2期

A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma. The investigational medicinal product AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct which is being developed to treat CD30-positive malignancies.
Patients who suffer from peripheral T-cell lymphoma or transformed mycosis fungoides, whose tumor expresses the surface marker CD30, and who have relapsed after an earlier treatment or have refractory disease will be enrolled into this study if all of the study entry criteria are fulfilled. Dependent on their disease type and the magnitude of CD30 expression, study participants will be assigned to one of 3 study cohorts, each cohort receiving the same treatment of weekly AFM13 infusions (a 200mg dose per infusion).
The main goal of the study is to assess the efficacy of AFM13 treatment as judged by the rate of overall responses. Further goals are to assess the safety of AFM13 treatment, the immunogenicity of AFM13 (as measured by the potential formation of anti-AFM13 antibodies) and the concentration of AFM13 in the blood.
Approx. 1 month after the last dose of AFM13 there will be a final study visit to assess the patients' health status after therapy, followed by quarterly phone contacts to check on their overall health status and long-term survival.

开始日期2019-11-13

申办/合作机构

Affimed GmbH

100 项与 Acimtamig 相关的临床结果

登录后查看更多信息

100 项与 Acimtamig 相关的转化医学

登录后查看更多信息

100 项与 Acimtamig 相关的专利（医药）

登录后查看更多信息

项与 Acimtamig 相关的文献（医药）

2025-01-06·CLINICAL CANCER RESEARCH

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas

Article

作者: Alexis, Karenza ; Zinzani, Pier Luigi ; Mikhailova, Natalia ; Shortt, Jake ; Horwitz, Steven ; Ravenstijn, Paulien ; Hajela, Pallavi ; Radeski, Dejan ; Garcia, Linta ; Elbadri, Riham ; Emig, Michael ; Pietzko, Kerstin ; Ribrag, Vincent ; Domingo Domenech, Eva ; Sawas, Ahmed ; Pinto, Sheena ; Kim, Won Seog ; Overesch, Andre

Abstract:

Purpose::

Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.

Patients and Methods::

Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival.

Results::

The overall response rate in 108 patients was 32.4% [95% confidence interval (CI), 23.7, 42.1] with a complete response rate of 10.2% (95% CI, 5.2, 17.5); the median duration of response was 2.3 months (95% CI, 1.9, 6.5). Patients with R/R angioimmunoblastic T-cell lymphoma exhibited the greatest number of responses [53.3% (95% CI, 34.3, 71.7)]. Responses were independent of CD30 expression level, prior brentuximab vedotin treatment, or steroid premedication. Acimtamig exhibited a tolerable safety profile; the most common treatment-related adverse events were infusion-related reactions in 27 patients (25.0%) and neutropenia in 11 patients (10.2%). No cases of cytokine release syndrome or acimtamig-related deaths were reported. Despite exhibiting promising clinical activity and tolerable safety in a heavily pretreated PTCL population, the study did not meet the criteria for the primary endpoint.

Conclusions::

The promising clinical efficacy observed warrants further investigation, and development of acimtamig for patients with R/R CD30+ lymphomas continues in combination with allogeneic NK cells.

2023-12-08·Hematology. American Society of Hematology. Education Program

The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure

Article

作者: Grover, Natalie S. ; Beaven, Anne W. ; Thakkar, Astha ; Dittus, Christopher

Abstract:

The treatment landscape of classical Hodgkin lymphoma has changed dramatically over the past decade. Relapsed and refractory mainstay therapeutics such as brentuximab vedotin (BV) and checkpoint inhibitors (CPIs) are being moved to earlier lines of therapy. However, the treatment of patients who progress after BV and CPI remains a challenge. Allogeneic stem cell transplantation still plays an important role in this patient population as the only current treatment approach with curative potential. Unfortunately, not all patients are transplant candidates, and many will still relapse afterward. Cytotoxic chemotherapy and radiation may be used for symptom palliation or as a bridge to transplant. Targeted therapies, including the antibody drug conjugate, camidanlumab tesirine, and transcriptional agents such mammalian target of rapamycin and histone deacetylase inhibitors have shown some potential in patients with refractory disease. In addition, combination therapies with CPIs and novel agents may help overcome resistance to therapy. Clinical trials with cellular therapies, including chimeric antigen receptor T cells targeting CD30 and allogeneic natural killer cells combined with AFM13, a CD30/CD16a-bispecific antibody, have shown promising results. The availability of more therapeutic options for this patient population is eagerly awaited.

2022-07-03·Leukemia & lymphoma

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Article

作者: Borchmann, Peter ; Tresckow, Bastian von ; Dietlein, Markus ; Hüttmann, Andreas ; Sasse, Stephanie ; Momotow, Jesko ; de Wit, Maike ; Thorspecken, Sven ; Bröckelmann, Paul Jan ; Engert, Andreas ; Grosse-Thie, Christina ; Plütschow, Annette ; Fuchs, Michael ; Martin, Sonja ; Basara, Nadezda ; Bentz, Martin ; Kobe, Carsten ; Koenecke, Christian

In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A-C), we initiated a randomized two-stage phase II trial (NCT02321592). Due to slow recruitment, the trial was terminated after treatment of 25 patients. Treatment with AFM13 was well tolerated: only two treatment-associated serious adverse events (SAEs) were reported; all SAEs resolved completely. With an objective response rate (ORR) of 16.7% (1/5 in arm A, 1/11 in arm B, and 2/8 in arm C) and a 12-month progression-free survival (PFS) of 12.6% (95% CI 3.2-28.9), treatment efficacy of AFM13 monotherapy in all evaluable patients was modest. The continuous application schedule (arm C) might be more effective, but the visit schedule should be better aligned with patients' daily life.

124

项与 Acimtamig 相关的新闻（医药）

2025-04-25

·ioncology

2025 ASCO大会前瞻丨血液肿瘤领域有哪些重磅研究入选？一文速览

点击蓝字关注我们编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。作为全球规模最大、学术水平最高、最具权威性的国际肿瘤会议之一，2025年ASCO年会将汇聚顶级肿瘤专家、学者和行业领袖，共探肿瘤领域的前沿研究成果和先进治疗方法。日前，2025 ASCO入选摘要标题（包括Late-Breaking Abstracts）已发布。摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布。《肿瘤瞭望-血液时讯》特别整理血液肿瘤领域的重磅研究，包括1项LBA、27项口头报告、27项快速口头报告，助力大家提前了解会议的重磅内容。01Plenary Session当地时间：6月1日13:00-16:00报告地点：Hall B1摘要号：LBA3英文标题：Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)中文标题：：rusfertide治疗真性红细胞增多症（PV）的三期、双盲、安慰剂（PBO）对照VERIFY研究结果讲者：Andrew Tucker Kuykendall, MD| Moffitt Cancer Center02Oral Abstract Session淋巴瘤与慢性淋巴细胞白血病当地时间：5月30日14:45–17:45报告地点：S100a摘要号：7000英文标题：Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial中文标题：通过PhasED-Seq对国家试验中DLBCL患者治疗结束ctDNA MRD的前瞻性验证讲者：Steven Wang, MD | Amsterdam UMC Location Vrije Universiteit摘要号：7001英文标题：Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group中文标题：自然杀伤性 T 细胞淋巴瘤分期系统修订：中国西南肿瘤学组及亚洲淋巴瘤研究组多中心研究讲者：林桐榆（四川省肿瘤医院）摘要号：7002英文标题：Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses中文标题：不同组织学分级滤泡性淋巴瘤的分子图谱：来自基因组和转录组分析的见解讲者：孙聪（天津医科大学肿瘤医院）摘要号：7003英文标题：A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)中文标题：KITE-363抗CD19/CD20嵌合抗原受体（CAR）T细胞治疗复发/难治性B细胞淋巴瘤患者的Ⅰ期临床研究讲者：Saurabh Dahiya, MD, FACP | Stanford University School of Medicine摘要号：7004英文标题：Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma中文标题：多病毒特异性T细胞用于增强双特异性抗体在淋巴瘤中的治疗活性讲者：Akiva Diamond, MD | Department of Medicine, Section of Hematology-Oncology, Baylor College of Medicine; Baylor St.Luke’s Medical Center; Dan L Duncan Comprehensive Cancer Center摘要号：7005英文标题：WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma中文标题：WaveLINE-003：zilovertamab vedotin联合标准治疗用于复发/难治性弥漫大B细胞淋巴瘤的Ⅱ/Ⅲ期临床试验讲者：Philippe Armand, MD, PhD | Dana-Farber Cancer Institute摘要号：7006英文标题：Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)中文标题：信迪利单抗（抗PD-1抗体）联合西达本胺（一种口服HDACi）继以 P-GemOx 方案治疗初治结外自然杀伤性 /T 细胞淋巴瘤（TN-ENKTL）患者的多中心、开放标签、单臂、II 期研究（SCENT-2 试验）讲者：黄慧强（中山大学肿瘤防治中心）摘要号：7007英文标题：Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21)中文标题：信迪利单抗（抗PD-1）联合依托泊苷（ICE）方案用于二线治疗经典霍奇金淋巴瘤（cHL）：一项多中心、随机、对照、双盲 III 期研究（ORIENT-21）的结果讲者：刘鹏（中国医学科学院肿瘤医院）摘要号：7008英文标题：Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)中文标题：先天细胞接合剂acimtamig（AFM13）联合AlloNK（AB-101）治疗复发或难治性经典型霍奇金淋巴瘤的Ⅱ期临床试验剂量探索部分结果（LuminICE-203）讲者：Joseph E. Maakaron, MD | Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：6月2日15:00-18:00报告地点：S100a摘要号：6500英文标题：Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial中文标题：Ropeginterferon alfa-2b vs. anagrelide治疗原发性血小板增多症：SURPASS-ET Ⅲ期临床试验的主要结果讲者：Ruben A. Mesa, MD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine摘要号：6501英文标题：Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)中文标题：asciminib（ASC）vs. nilotinib（NIL）用于新诊断慢性期慢性粒细胞白血病（CML-CP）患者的不良事件导致治疗中断时间（TTDAE）:ASC4START Ⅲb期临床试验主要终点结果讲者：Andreas Hochhaus, MD | Klinik für Innere Medizin II, Universitätsklinikum Jena摘要号：6502英文标题：Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study中文标题：CADENZA研究中pivekimab sunirine（PVEK）治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）患者的疗效与安全性讲者：Naveen Pemmaraju, MD | The University of Texas MD Anderson Cancer Center摘要号：6503英文标题：Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes中文标题：克拉屈滨、低剂量阿糖胞苷联合维奈克拉与阿扎胞苷联合维奈克拉交替治疗高危慢性粒单核细胞白血病和骨髓增生异常综合征的Ⅱ期临床研究讲者：Guillermo Montalban-Bravo, MD | The University of Texas MD Anderson Cancer Center摘要号：6504英文标题：An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts中文标题：全口服方案decitabine-cedazuridine（DEC-C）联合维奈克拉（VEN）用于不适合强化诱导化疗的新诊断急性髓系白血病（AML）患者：来自101例患者的Ⅱ期队列研究结果讲者：Amer Methqal Zeidan, MBBS | Yale University School of Medicine摘要号：6505英文标题：Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies中文标题：lisaftoclax（APG-2575）联合阿扎胞苷（AZA）治疗初治或既往接受过维奈克拉（VEN）治疗的髓系恶性肿瘤患者的Ⅰb/Ⅱ期临床研究讲者：Michael Francis Leahy, FRACP, FRCP, FRCPath, MBChB | Royal Perth Hospital摘要号：6506英文标题：Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study中文标题：Ziftomenib治疗复发/难治性（R/R）NPM1突变急性髓系白血病（AML）：关键KOMET-001研究中Ⅰb/Ⅱ期临床疗效和安全性结果讲者：Eunice S. Wang, MD | Roswell Park Comprehensive Cancer Center摘要号：6507英文标题：γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION中文标题：γ9δ2 T细胞激活（γδTCA）联合ICT01和阿扎胞苷-维奈克拉（AV）治疗高龄/unfit新诊断急性髓系白血病（AML）成年患者：EVICTION Ⅰ/Ⅱ期研究中的初步疗效和剂量选择讲者：Pierre Yves Dumas, MD, PhD| CHU摘要号：6508英文标题：Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation中文标题：接受异基因造血干细胞移植后存活超过2年患者的长期结局讲者：Arjun Datt Law, MD, DM, MBBS, FCRP | Princess Margaret Cancer Centre浆细胞病当地时间：6月3日09:45-12:45报告地点：S100bc摘要号：7500英文标题：MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial中文标题：在适合移植的新诊断多发性骨髓瘤（NDMM）患者中，IsaKRD诱导后MRD驱动策略：MIDAS Ⅲ期临床试验的主要终点讲者：Aurore Perrot, MD, PhD | Toulouse University, CHU Oncopole摘要号：7501英文标题：Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial中文标题：皮下注射达雷妥尤单抗（Dara）+硼替佐米/来那度胺/地塞米松（VRd）联合达雷妥尤单抗+来那度胺（DR）维持治疗适合移植（TE）新诊断多发性骨髓瘤（NDMM）患者：PERSEUS Ⅲ期临床试验中持续微小残留病（MRD）阴性的分析讲者：Philippe Moreau, MD, PhD | University Hospital Hôtel-Dieu摘要号：7502英文标题：Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)中文标题：卡非佐米-来那度胺-地塞米松联合或不联合艾沙妥昔单抗（Isatuximab）治疗新诊断多发性骨髓瘤患者：Ⅲ期IsKia临床试验中的持续微小残留病（MRD）阴性分析讲者：Francesca Gay, MD, PhD | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino摘要号：7503英文标题：Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial中文标题：卡非佐米、来那度胺和地塞米松（KRd）联合或不联合达雷妥尤单抗（D）治疗新诊断多发性骨髓瘤（NDMM）患者的随机多中心研究：ADVANCE临床试验讲者：Carl Ola Landgren, MD, PhD | Myeloma Program and Experimental Therapeutics Program, University of Miami摘要号：7504英文标题：Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1中文标题：Elranatamab联合达雷妥尤单抗和来那度胺（EDR）治疗不适合接受移植的新诊断多发性骨髓瘤（NDMM）患者：MagnetisMM-6 part 1的初步结果讲者：HANG QUACH, MD, FRACP, FRCPA | St Vincent’s Hospital Melbourne, University of Melbourne摘要号：7505英文标题：First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results中文标题：JNJ-79635322（JNJ-5322）新型三特异性抗体（TsAb）在复发/难治性多发性骨髓瘤（RRMM）患者中的首次人体研究：初步Ⅰ期结果讲者：Niels W.C.J. van de Donk, MD, PhD | Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology摘要号：7506英文标题：Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study中文标题：艾沙妥昔单抗（Isa）通过体外输送系统（OBDS）皮下（SC）给药vs. Isa静脉注射（IV），联合泊马度胺和地塞米松（Pd）治疗复发/难治性多发性骨髓瘤（RRMM）：随机非劣效性Ⅲ期IRAKLIA研究结果讲者：Xavier P. Leleu, MD, PhD | Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402摘要号：7507英文标题：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)中文标题：CARTITUDE-1研究中接受ciltacabtagene autoleucel（cilta-cel）治疗的复发/难治性多发性骨髓瘤（RRMM）患者的长期（≥5年）缓解与生存情况讲者：Peter M. Voorhees, MD | Atrium Health / Levine Cancer Institute, Wake Forest University School of Medicine摘要号：7508英文标题：Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201中文标题：Nexicart-2的安全性与疗效数据：CAR-T在R/R轻链淀粉样变中的首次美国试验（Nxc-201）讲者：Heather Jolie Landau, MD | Memorial Sloan Kettering Cancer Center03Rapid Oral Abstract Session白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：5月30日13:00-14:30报告地点：E450a摘要号：6509英文标题：A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults中文标题：asciminib联合达沙替尼、泼尼松和贝林妥欧单抗治疗成人Ph阳性急性白血病的Ⅰ期临床研究讲者：Marlise R Luskin, MD | Dana-Farber Cancer Institute摘要号：6510英文标题：MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis中文标题：PhALLCON Ⅲ期临床试验中诱导治疗结束后的MRD阴性率：事后分析讲者：Ibrahim Aldoss, MD | City of Hope – Duarte摘要号：6511英文标题：Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation中文标题：减量PTCy用于接受配型无关供者异基因造血干细胞移植的急性髓系白血病患者讲者：Nihar Desai, MD, DM | Princess Margaret Hospital摘要号：6512英文标题：Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial中文标题：COMMANDS研究中luspatercept（LUSPA）对比促红素α（epoetin alfa，EA）治疗未使用促红素治疗的极低、低或中危骨髓增生异常综合征（MDS）患者的总体生存期（OS）与获得输血独立（TI）后反应持续时间分析讲者：Guillermo Garcia-Manero, MD | University of Texas MD Anderson Cancer Center摘要号：6513英文标题：Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study中文标题：bexmarilimab联合阿扎胞苷抑制巨噬细胞检查点Clever-1治疗骨髓增生异常综合征的疗效：BEXMAB Ⅰ/Ⅱ期研究结果讲者：Naval Guastad Daver, MD | Department of Leukemia, The University of Texas MD Anderson Cancer Center摘要号：6514英文标题：Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML中文标题：地西他滨和维奈克拉用于诱导终末分化，以改善TP53突变型MDS和AML的治疗结局讲者：Mendel Goldfinger, MD | Montefiore Einstein Comprehensive Cancer Center摘要号：6515英文标题：IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF)中文标题：IMproveMF更新：imetelstat（IME）联合芦可替尼（RUX）治疗中危1（INT-1）、中危2（INT-2）或高危（HR）骨髓纤维化（MF）患者的Ⅰ/Ⅰb期临床试验讲者：John Mascarenhas, MD | Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai摘要号：6516英文标题：Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial中文标题：asciminib（ASC）治疗接受过1种酪氨酸激酶抑制剂（TKI）治疗的慢性期慢性髓性白血病（CML-CP）患者的疗效和安全性：Ⅱ期ASC2ESCALATE试验的中期分析（IA）讲者：David Jacob Andorsky, MD | Rocky Mountain Cancer Centers, US Oncology Research摘要号：6517英文标题：Age-related macular degeneration in individuals with clonal hematopoiesis中文标题：克隆性造血个体的年龄相关性黄斑变性讲者：Keishla Marie Arce-Ruiz, BS | McGraw/Patterson Center for Population Sciences, Dana-Farber Cancer Institute淋巴瘤与慢性淋巴细胞白血病当地时间：5月31日08:00-09:30报告地点：E450a摘要号：7009英文标题：Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D中文标题：zanubrutinib（zanu）联合维奈克拉（ven）治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）：SEQUOIA研究D组结果讲者：Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Center and University of Washington摘要号：7010英文标题：Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders中文标题：DZD8586 在经共价或非共价 BTK 抑制剂及 BTK 降解剂治疗后的 CLL/SLL 患者中的I/II期研究讲者：李建勇（江苏省人民医院）摘要号：7011英文标题：SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)中文标题：SEQUOIA研究5年随访，C组：前线zanubrutinib单药治疗del(17p)及未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者讲者：Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS | Alfred Hospital and Monash University摘要号：7012英文标题：A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma中文标题：一项1/2期研究：评估选择性 EZH2 抑制剂 XNW5004 在复发/难治性非霍奇金淋巴瘤患者中的安全性与有效性讲者：邱录贵[中国医学科学院血液病医院（中国医学科学院血液学研究所）]摘要号：7013英文标题：CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study中文标题：以 CD79b 为靶点的抗体偶联药物（ADC）SHR - A1912 联合R - GemOx方案用于复发 / 难治性（R/R）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的1b/2期研究数据讲者：李亚军（湖南省肿瘤医院）摘要号：7014英文标题：Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study中文标题：固定疗程皮下（SC）莫妥珠单抗（Mosun）治疗既往未治疗的高肿瘤负担滤泡性淋巴瘤（FL）患者：Ⅱ期MorningSun研究的中期结果讲者：Ian W. Flinn, MD, PhD | Tennessee Oncology and OneOncology摘要号：7015英文标题：Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO中文标题：格菲妥单抗联合吉西他滨和奥沙利铂（Glofit-GemOx）治疗复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者：STARGLO研究2年随访结果讲者：Jeremy S. Abramson, MD | Massachusetts General Hospital Cancer Center摘要号：7016英文标题：Worldwide experience of chronic active EBV infection: Retrospective cohort study中文标题：全球慢性活动性EBV感染经验：回顾性队列研究讲者：王欣然（华中科技大学同济医学院附属同济医院）摘要号：7017英文标题：Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study中文标题：伊布替尼联合维奈克拉一线治疗年龄较大或存在TP53突变的套细胞淋巴瘤（MCL）患者的疗效和安全性：SYMPATICO研究讲者：Michael Wang, MD | Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center创新性治疗—免疫疗法当地时间：6月1日11:15-12:45报告地点：S406摘要号：2514英文标题：Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL)中文标题：靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果讲者：李志铭（中山大学肿瘤防治中心）浆细胞病当地时间：6月2日08:00-09:30报告地点：E450b摘要号：7509英文标题：Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial中文标题：艾沙妥昔单抗、卡非佐米、来那度胺和地塞米松（Isa-KRd）治疗高危（HR）新诊断多发性骨髓瘤（NDMM）：GMMG-CONCEPT研究中适合移植（TE）患者全队列的首次报告讲者：Lisa B. Leypoldt, MD | University Medical Center Hamburg-Eppendorf摘要号：7510英文标题：Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合硼替佐米（BTZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的首次结果讲者：Xavier P. Leleu, MD, PhD | Hematology, CIC 1082, U1313, CHU, University摘要号：7511英文标题：Heterogeneity in the expression of GPRC5D between patients with multiple myeloma中文标题：多发性骨髓瘤患者中GPRC5D表达的异质性讲者：Harsh Parmar | John Theurer Cancer Center, Hackensack University Medical Center摘要号：7512英文标题：Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial中文标题：Belantamab mafodotin联合来那度胺/地塞米松治疗新诊断的中度fit和虚弱多发性骨髓瘤患者：来自Ⅰ/Ⅱ期BELARD临床试验的长期疗效和安全性结果讲者：Evangelos Terpos, MD, PhD | Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine摘要号：7513英文标题：Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合卡非佐米（CFZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的初步结果讲者：Salomon Manier, MD, PhD | Hematology Department, Lille University Hospital摘要号：7514英文标题：Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results中文标题：ISB 2001的Ⅰ期首次人体研究：一种针对BCMAxCD38xCD3的三特异性抗体治疗复发/难治性多发性骨髓瘤（RRMM）患者——剂量递增（DE）结果讲者：Eben I. Lichtman, MD | UNC Lineberger Comprehensive Cancer Center摘要号：7515英文标题：Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial中文标题：belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺、硼替佐米和地塞米松（PVd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的微小残留病（MRD）阴性率比较：来自DREAMM-8研究的分析讲者：Suzanne Trudel, MD | Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre摘要号：7516英文标题：Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study中文标题：达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松（DVRd）治疗新诊断多发性骨髓瘤（NDMM）患者：Ⅲ期CEPHEUS研究中不适合移植（TIE）患者的亚组分析讲者：Saad Z Usmani, MD, MBA, FRCP, FASCO | Memorial Sloan Kettering Cancer Center（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果ASCO会议临床1期细胞疗法免疫疗法

2025-04-23

·小药说药

CD16a生物学与ADCC作用

-01-引言抗体依赖性细胞介导的细胞毒性（ADCC）是一种有效的细胞毒性机制，主要通过自然杀伤（NK）细胞介导。当特异性抗体结合到靶向细胞膜上以后，免疫细胞通过该反应诱导细胞死亡。这是抗体限制和控制感染的几种主要机制之一。抗体和免疫细胞的相互作用通过一个受体家族发生：Fc受体（FcR）。在人类中，IgG的FcR家族（FcγR）由6个受体组成：FcγRI/CD64、FcγRIIa/CD32a、FcγRIIb/CD32b、FcγRIIc/CD32c、FcγRIIIa/CD16a和FcγRIIIb/CD16b，其中CD16a主要负责触发NK细胞介导的ADCC。因此，对CD16a作用机制的了解，有助于我们通过改善单克隆抗体或NK细胞来增强肿瘤免疫治疗药物的ADCC作用。-02-一、ADCC的作用机制NK细胞是一种天然的淋巴细胞，能够非常有效地破坏应激细胞，如病毒感染或肿瘤转化细胞。通常情况下，ADCC效应主要通过结合FCR的抗体激活NK细胞，NK细胞膜上最具特征的FcR就是FcγRIII（CD16），其中NK细胞主要表达CD16a，而CD16b仅限于中性粒细胞。人类NK细胞分为两个主要亚群：CD56bright和CD56dim。CD56brightNK细胞是强有力的细胞因子产生者，但缺乏CD16a；而CD56dim具有高度的细胞毒性，表达D16a。当通过CD16a识别IgG调理的靶点时，NK细胞就会释放不同的细胞毒性分子，从而引发靶细胞的死亡。这种机制依赖于免疫突触的形成和含有穿孔素和颗粒酶的溶解颗粒的脱颗粒。除了脱颗粒外，NK细胞还可以通过将靶死亡受体（如DR4、DR5或Fas）与其死亡受体配体（如FasL和TRAIL）结合来清除靶细胞。-03- 二、CD16a的生物学CD16a是一种跨膜受体，具有短的C-ter胞质尾，并具有两个细胞外Ig样结构域。它的细胞内部分不具有任何信号成分，因此，为了传递信号，它需要两条带有免疫受体酪氨酸基激活基序（ITAM）的信号链。CD16a与IgG的CH2以1:1的方式相互作用，其中CH2上的N297位的 N-聚糖链在这种相互作用中也起着关键作用。因此，不仅氨基酸序列，其聚糖组成都可以极大地影响CD16a对Fc的亲和力，从而影响ADCC的效力。CD16a在其细胞质尾部不具有任何ITAM结构域，因此需要两条含有ITAM结构域的细胞内链串联的帮助，CD3ζ和FcϵRIγ。CD16a结合后，属于Src家族的激酶Lck被激活，并磷酸化CD3ζ和/或FcϵRIγ的ITAM结构域。磷酸化的ITAM允许来自Syk家族的激酶招募和磷酸化，例如Syk和ZAP-70，它们反过来负责后续的信号传导。在它们的底物中，PI3K是高度相关的，因为它将PIP2转化为PIP3，PIP3经PLC-γ处理后释放IP3和DAG。DAG激活PKC家族，这有助于触发脱颗粒。IP3诱导钙从内质网释放，这种钙内流是ADCC触发的主要信号之一，也导致核内NFAT易位，诱导其靶基因的转录。CD16a参与激活的其他途径也有助于ADCC，例如ERK2 MAPK途径。CD16a依赖性NK细胞杀伤后，CD16a迅速下调。CD16a脱落的机制之一是由去整合素和金属蛋白酶17（ADAM17）介导的，后者在NK细胞上表达。ADAM17对CD16a的切割发生在顺式结构中，这意味着表达ADAM17的NK细胞不能在另一个NK细胞上诱导CD16a脱落。激活后CD16a下调的另一个机制是内化，这不仅发生在CD16a上，也发生在其他细胞内信号成分上，如CD3ζ、ZAP-70和Syk。-04-三、提高ADCC作用的策略细胞因子提高ADCC活性的一个简单方法是用促炎细胞因子刺激NK细胞。NK细胞移植已在多个临床试验中成功进行，例如通过输注细胞因子诱导记忆样（CIML）NK细胞，最常用的细胞因子组合包括IL-12、IL-15和IL-18。CIML NK细胞比传统NK细胞表达更多的IFN-γ，对白血病细胞和原发性急性髓系白血病（AML）母细胞显示出优越的细胞毒性。IL-12会增加NK细胞产生IFN-γ和TNF-α，在一项I/II期临床试验中，西妥昔单抗与IL-12联合应用于无法切除或复发的头颈部鳞状细胞癌患者。与无进展生存期（PFS）小于100天的患者相比， PFS大于100天的患者NK细胞在体外具有更高的ADCC活性。IL-15是NK和CD8+T细胞生存和功能所必需的细胞因子。N-803是一种突变的N72D IL-15超激动剂，在临床前模型和临床试验中显示出增强的NK细胞体外和体内活性。此外，它还增加了NK和CD8+T细胞的数量。抑制ADAM17ADAM17是激活后CD16a下调的主要驱动因素。改善NK细胞ADCC的一种策略是通过靶向ADAM17来防止CD16a脱落。研究发现，对NK细胞中使用CRISPR/Cas9技术敲除ADAM17，显示出更好的IFN-γ生成和体内外ADCC活性。然而，也有研究显示，阻断ADAM17降低了NK细胞的存活率以及CD16a介导的连环杀伤，细胞无法与靶细胞分离，阻碍其运动到另一个靶细胞。总之，ADAM17抑制的益处尚不清楚，结果也有争议。这一策略是否能够成功，有待于一项正在进行的临床试验（NCT04023071）结果，该试验将评估携带不可切割CD16a的iPSC衍生NK细胞在AML和B细胞淋巴瘤中的应用。工程化抗体抗体的Fc部分进行工程化改造，可以增加Fc对CD16a的亲和力，并随后改善ADCC。一些突变非常流行，例如，所谓的GASDALIE，由Fc中的4个替换组成：G236A/S239D/A330L/I332E。该突变显示对CD16a的亲和力显著增加，而CD32b亲和力几乎没有增加。另一个突变称为突变体18（F243L/R292P/Y300L/V305I/P396L），ADCC显著增加。这些突变现已作为抗HER2抗体margetuximab进入临床，并在I期治疗各种HER2阳性癌时显示出良好的效果。此外，抗体Fc N-聚糖的糖工程化有望增加对CD16a的亲和力。研究最多的糖修饰是去糖基化，例如去岩藻糖修饰。这种修饰导致与CD16a的结合增加，ADCC改善。这项技术已被用于抗CD20抗体obinutuzumab。NK细胞接合器除了工程化抗体之外，还可以研究抗体的形式。基于双特异性T细胞接合器（BiTE）策略的成功，为NK细胞开发了一种类似的形式，即所谓的双特异性杀伤细胞接合器（BiKE）。BiKE由两个scFv通过连接序列组成，一个单链抗体靶向CD16a，另一个靶向肿瘤抗原。此外，还有三特异性杀伤细胞接合器（TRiKE），有2种肿瘤抗原与CD16a一起被靶向，或者添加IL-15代替第三种单链抗体。这种结构的使用允许NK细胞重新定位到肿瘤细胞，并导致针对靶细胞的强大ADCC作用。AFM13是一种针对CD16a和CD30的双特异性抗体，目前处于临床Ⅱ期，用于治疗外周T细胞淋巴瘤、转化型蕈样变性和霍奇金淋巴瘤。在一项治疗复发或难治性霍奇金淋巴瘤的Ib临床研究中，AFM13与pembrolizumab的联合治疗产生了88%的客观反应率，总反应率为83%。GTB-3550是一种CD16/CD33/IL-15的TRiKE形式，目前正在进行多种类型白血病的I/II期试验研究（NCT03214666）。调节代谢途径代谢失调是肿瘤微环境中免疫抑制的关键驱动因素，许多研究已经表明，免疫细胞代谢对其功能至关重要。最近，一些代谢药物在增强NK细胞活性方面显示出有希望的结果。二甲双胍，被证明可以增加免疫细胞配体的表达，尤其是ICAM-1的表达。ICAM-1是一种整合素，可以调节淋巴细胞细胞内信号，包括NK细胞。二甲双胍与UCB联合使用扩增NK细胞在体外和体内显示出更高的肿瘤细胞清除率。此外，另一种策略是直接调节NK细胞代谢。cMyc是调节小鼠NK细胞糖酵解和氧磷代谢机制的关键因子，缺乏cMyc会导致NK细胞反应受损。糖原合成酶激酶-3（GSK3）可介导小鼠NK细胞中cMyc的降解。与此一致，在AML患者的NK细胞中检测到GSK3过度表达，并与针对AML细胞的细胞毒性受损有关，GSK3抑制剂可恢复这些NK细胞的活性。目前，一些临床试验正在评估GSK3抑制剂LY2090314对实体癌和血液癌的疗效（NCT01632306、NCT01287520和NCT01214603）。-05-结语自然杀伤细胞是一组独特的抗肿瘤效应细胞，具有不受MHC限制的细胞毒性、产生细胞因子和免疫记忆等功能，使其成为先天性和适应性免疫反应系统中的关键角色。通过CD16a的ADCC作用是NK细胞发挥效应器功能的主要机制之一。因此，对CD16a的生物学的深入了解有助于我们找到增强ADCC作用的策略，从而提高NK细胞的抗肿瘤活性。参考资料：1.From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement. Front Immunol.2022; 13: 913215.公众号内回复“ADC”或扫描下方图片中的二维码免费下载《抗体偶联药物：从基础到临床》的PDF格式电子书！公众号已建立“小药说药专业交流群”微信行业交流群以及读者交流群，扫描下方小编二维码加入，入行业群请主动告知姓名、工作单位和职务。

细胞疗法抗体药物偶联物免疫疗法

2025-04-23

·GlobeNewswire-Health Care

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations. Details of the acimtamig oral presentation and AFM24 poster presentations are as follows: Abstract Title & NumberDate & Time Session Type & TitleResults from the completed dose-finding part of a phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)Abstract Number for Publication: 7008May 30, 20252:45 PM-5:45 PM CDTOral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic LeukemiaBispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a studyAbstract Number for Publication: 2609June 2, 20251:30 PM-4:30 PM CDTPoster Session – Developmental Therapeutics—ImmunotherapyPoster Board: 256Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a studyAbstract Number for Publication: 2610 June 2, 20251:30 PM-4:30 PM CDTPoster Session – Developmental Therapeutics—ImmunotherapyPoster Board: 257 The full abstracts will be published online on May 22, 2025. More details about the programs for the 2025 ASCO Annual Meeting are available online at Attend | ASCO Annual Meeting. About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com. Investor Relations Contact Alexander FudukidisDirector, Investor RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917) 436-8102 Media Contact Mary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: m.sandin@affimed.com

临床2期免疫疗法ASCO会议临床结果

100 项与 Acimtamig 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
CD30阳性外周T细胞淋巴瘤	临床2期	美国	Affimed GmbH	2023-10-10
复发性霍奇金淋巴瘤	临床2期	美国	Affimed GmbH	2023-10-10
复发性B细胞淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
难治性B细胞淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
CD30阳性非霍奇金淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
难治性外周T细胞淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
复发性间变性大细胞淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
难治性经典霍奇金淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
难治性间变性大细胞淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18
复发性经典霍奇金淋巴瘤	临床2期	美国	The University of Texas MD Anderson Cancer Center	2020-07-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04074746 (Pubmed) 人工标引	临床1期	淋巴瘤 TNFRSF8 Positive	42	AFM13	窪積壓範願積構餘構窪(鬱願鏇網願襯鹽糧窪蓋) = 夢範鏇憲願齋餘憲蓋醖鹽鹹構壓顧膚簾網遞艱 (顧獵顧願鹹蓋範顧襯積 ) 更多	积极	2025-04-04
NCT05883449 (LuminICE-203, NEWS) 人工标引	N/A	难治性霍奇金淋巴瘤	7	acimtamig+AlloNK	鏇醖遞鬱簾醖糧觸顧鏇(壓襯鬱觸構夢壓糧醖壓) = 選構淵鏇壓齋廠膚憲範齋膚壓糧繭簾艱鑰糧願 (選鏇艱構醖窪夢鏇壓鹽 ) 更多	积极	2024-06-13
NCT04074746 (ASH2023) 人工标引	临床1/2期	CD30阳性淋巴瘤 TNFRSF8 Positive	42	Anti-CD30/anti-CD16A antibody (Affimed)+NK	網襯廠鑰範構顧築廠選(築壓鹽鏇夢鏇鏇淵襯醖) = 餘鹽鬱積齋壓鏇壓顧構膚餘餘廠淵憲選鬱網鹹 (襯鑰獵齋齋遞鏇膚願遞 ) 更多	积极	2023-12-11
NCT03192202 (not available, CTgov)	临床1/2期	CD30阳性淋巴瘤 \| 皮肤T细胞淋巴瘤 \| 淋巴瘤样丘疹病 ... 更多	18	AFM13 (Cohort 1)	艱選積齋憲淵遞膚簾積 = 餘願範憲夢憲壓簾願網壓窪鏇築網鑰鏇構艱顧 (鹽繭衊鬱鬱選襯網鹹憲, 餘夢鬱衊鑰鏇鬱憲夢鹽 ~ 願鑰艱遞襯襯顧夢廠廠) 更多	-	2023-07-20
NCT03192202 (not available, CTgov)	临床1/2期	CD30阳性淋巴瘤 \| 皮肤T细胞淋巴瘤 \| 淋巴瘤样丘疹病 ... 更多	18	AFM13 (Cohort 2)	艱選積齋憲淵遞膚簾積 = 選觸簾鬱襯積選壓鏇齋壓窪鏇築網鑰鏇構艱顧 (鹽繭衊鬱鬱選襯網鹹憲, 廠齋觸鏇淵鹹簾壓網蓋 ~ 遞淵憲艱鏇獵鹽衊窪鏇) 更多	-	2023-07-20
NCT04101331 (REDIRECT, ICML2023)	临床2期	外周T细胞淋巴瘤 \| 蕈样真菌病 \| CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma ... CD30 positive 更多	108	AFM13 200 mg	選糧簾遞築鹽獵繭蓋壓(衊鹽構鹹遞膚憲鏇選鑰) = 壓網鬱簾鬱膚鬱願醖顧積衊餘淵淵廠廠網齋積 (製獵醖鏇鏇蓋艱範餘夢 ) 更多	积极	2023-06-09
NCT04101331 (REDIRECT, EHA2023)	临床2期	外周T细胞淋巴瘤	108	AFM13	糧蓋醖網廠齋醖淵糧餘(築鹽膚膚鬱築獵鏇遞醖) = 構顧衊積醖醖糧構觸觸艱夢築窪選繭鹽願築築 (壓範願憲獵襯壓餘夢鏇 ) 更多	-	2023-06-08
NCT04101331 (REDIRECT, CTgov)	临床2期	外周T细胞淋巴瘤 \| 蕈样真菌病 \| CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma ... 更多	108	AFM13	膚鹹艱鬱觸膚範壓蓋遞 = 鹹淵鹹壓觸鬱淵憲製遞艱窪齋鬱窪醖糧願餘蓋 (網膚鹽觸淵鹹觸壓範鏇, 積築網餘夢範範簾鬱製 ~ 壓憲淵願簾憲憲鏇鏇觸) 更多	-	2023-06-05
NCT04101331 (REDIRECT, AACR2023) 人工标引	临床2期	CD30阳性外周T细胞淋巴瘤 CD30 Positive	108	AFM13 200 mg	範淵簾觸鑰鹹夢膚齋糧(範齋壓鏇築艱艱壓顧獵) = 蓋襯觸窪築選襯醖繭廠艱選簾窪構鏇襯鹹窪憲 (衊鏇襯鏇醖積簾蓋網醖 ) 更多	积极	2023-04-14
NCT04101331 (REDIRECT, AACR2023) 人工标引	临床2期	CD30阳性外周T细胞淋巴瘤 CD30 Positive	108	AFM13 200 mg (PTCL not-otherwise-specified (PTCL-NOS))	範淵簾觸鑰鹹夢膚齋糧(範齋壓鏇築艱艱壓顧獵) = 網鬱簾襯遞壓廠廠繭鹹艱選簾窪構鏇襯鹹窪憲 (衊鏇襯鏇醖積簾蓋網醖 )	积极	2023-04-14
NCT04101331 (REDIRECT, Corporate Publications) 人工标引	临床2期	外周T细胞淋巴瘤	145	AFM 13	製構餘膚艱襯選製積艱(憲選製齋艱遞壓繭製鬱) = 襯簾窪製簾廠廠襯襯廠顧齋齋製構艱鏇鏇衊繭 (範積艱糧遞鑰壓選膚製 ) 更多	积极	2022-12-10
NCT04074746 (ASH 12022 \| ASH 22022) 人工标引	临床1/2期	CD30阳性淋巴瘤	30	fludarabine or cyclophosphamide+AFM13	鏇齋製膚簾糧艱鏇範艱(繭鑰鏇網網憲膚襯衊鹹) = 製壓獵鹹範觸範糧繭糧願顧齋簾網艱築觸膚窪 (夢鹽艱齋繭壓窪構網鬱 ) 更多	积极	2022-11-15